May 07–10, 2026 | Park Plaza Riverbank London, London, United Kingdom
Scientific Organizers:
Karen Akinsanya, Alexander Hillisch, Najat Khan, and Gang Liu
-
Scientific Organizers: Karen Akinsanya, Alexander Hillisch, Najat Khan, and Gang Liu
Karen Akinsanya, PhD
Schrödinger
Alexander Hillisch
UCB BioSciences GmbH
Najat Khan, PhD
Recursion Pharmaceuticals
Gang Liu, PhD
Bill & Melinda Gates Foundation
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandBooking Function
Thursday, May 7, 2026
Fundraising
Merchandise Options
Registration Options
Friday, May 8, 2026
Development and Application of an AI-First Drug Design Platform at Isomorphic Labs
Computational Drug Design across Different Modalities
Avoiding Funnels: Using Active Learning and Generative AI to Drive Drug Discovery
Drugging the Undruggable: Leveraging Computational Techniques to Drive Compound Design
Short Talk: Discovery of a Nanomolar Active Molecule Using an Integrated Workflow Comprising AI, Physics and Experiment
Scalable Drug Discovery and Disease Interception by Unlocking Preclinical Molecular Signals from 100 Million Longitudinal Plasma Samples
Multiplexing Platform for Predictive Modeling of Context-dependent Cell Signaling to Enable Pluripotent Stem Cell-based Disease Models
Structure-guided Targeting of CMV for Synergistic Neutralization
Fast and Reliable Quantum Mechanical Scoring for Protein-Ligand Affinity Prediction in Structure-Based Drug Design
Federated Training of Multi-Task ADMET Models Across Distributed Pharmaceutical Data
Integrating Drug-Target Profiling and Network Diffusion for Generalizable Prediction of Kinase Inhibitor Response in Patient-Derived Xenografts
Remote Presentation: Peptide-MHCI (pMHCI) Binder Design
Harnessing Generative AI to Creation and Development of ABS-201: A Novel Anti-PRLR Antibody for Androgenic Alopecia
in silico Antibody Design
Short Talk: Generative Control of Antibody Dynamics: Fine-Tuning ProteinMPNN for Flexibility-Guided In Silico Maturation
Short Talk: Does Disorder Drive Barrier Crossing? Predicting Peptide Penetration from Disorder Features
Saturday, May 9, 2026
Fully AI-native Small Molecule Drug Discovery Based on Complex Cellular Phenotypic Models
Holistic De Novo Drug Design at UCB
Complete Allosteric Maps for Drug Discovery
Short Talk: Multi-Agent AI Enables Evidence-Based Cell Type Annotation for Drug Discovery
Short Talk: Large-Scale Proteomics for AI/ML applications: insights from quantifying 1,000 proteins in 20,000 samples
Director
Senior Editor
Digital Twins and In Silico Clinical Trials for Drug Discovery
Decoding Toxicology: Computational Frameworks for Next-Generation Predictive Safety
Human iPSC High-throughput Screening for Teratogenicity Hazard Identification
Short Talk: Predictive Toxicology: A Physics-Based Cloud Workflow for Mitigating Off-Target Liabilities
Sunday, May 10, 2026
Navigating Drug Development with Immune Intelligence
Making Drug Discovery for Rare Cancers
Measuring the Mind: Enabling the Next Era of Brain Drug Development
Short Talk: Interpretable Graph Neural Networks for Learning Drug–Gene Relationships and Inferring Phenotype Outcomes in Pharmacogenomics
Short Talk: Temporal Biodynamics: An AI Platform for Stage-Relevant Target Identification in Chronic Disease Progression
Diverse Application of AI in Drug Discovery at Novartis
Generative AI-Enabled Hit identification & Lead Optimization in Early Drug Discovery
Short Talk: Molecular Insights into the Anti-diabetic Activity of Ethanol Fractions of Cocos Nucifera (Coconut) Husk on Gestational Diabetes: An in silico Study
Short Talk: Disrupting the Mycobacterium tuberculosis Protein Tyrosine Kinase A and Protein tyrosine Phosphatase B Virulence Network: Integrated Computational and Experimental Identification of Novel Pyridine and Diazepane Derivatives as Potent Inhibitors
Monday, May 11, 2026
Subscribe for Updates